The increasing efficacy of breast cancer treatment

Clinical Oncology

Volumn 9, Issue 5, 1997, Pages 338-342

  Gordon, A ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Adjuvant therapy; Breast; Cancer; Chemotherapy; Immunotherapy; Molecular biology

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; FLUOROURACIL; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BLOCKING AGENT; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AXILLA; BREAST; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CYTOLOGY; FEMALE; GENE THERAPY; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; METASTASIS; MOLECULAR BIOLOGY; ONCOGENE; PARTIAL MASTECTOMY; PECTORAL MUSCLE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030704638     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(05)80069-X     Document Type: Article

References (53)

1. Underwood JCE. 1992. Tumours; benign and malignant. In: Underwood JCE, editor. General and systemic pathology. Edinburgh: Churchill Livingstone, 223-46.
2. Elledge RM, McGuire WL. Prognostic factors and therapeutic decisions in axillary non-negative breast cancer. Annu Rev Med 1993;44:201-10.
3. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott, 1993:1264-332.
4. Fisher B, Redmond C, Fisher ER. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumour biology; an overview of findings. Cancer 1980;46(Suppl):1009-25.
5. Liotta LA, Stetler-Stevenson WG. 1992. Principles of molecular cell biology of cancer: cancer metastasis. In: DeVita VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia, PA: Lippincott, 114-33.
6. Cassileth BR, Lusk EJ, Miller DS, et al. Psychosocial correlates of survival in advanced malignant disease. N Engl J Med 1985;312:1551-5.
7. Canellos GP, Hellman S, Veronesi U. The management of early breast cancer. N Engl J Med 1982;306:1430-3.
8. Keane P, Sikora K, Waxman J, et al. Breast. In: Sikora K, Halnan KE, editors. Treatment of cancer. London: Chapman and Hall, 1990:369-88.
9. Mueller C. Surgery for breast cancer. N Engl J Med 1985;312:712-4.
10. Diamandopoulous GT, Meissner WA. Neoplasia. In: Kissane JM, editor. Anderson's pathology. St Louis, MO: Mosby, 1996:513-47.
11. Hall J, Cox JD. Physiological and biological basis of radiation therapy. In: Moss WT, Cox JD, editors. Radiation oncology. St Louis, MO: Mosby, 1989:1-57.
12. Turrisi AT, Glatstein E. Principles of combined radiotherapy and chemotherapy. In: Moss WT, Cox JD, editors. Radiation oncology. St Louis, MO: Mosby, 1989:68-82.
13. Mazeren JJ, Otmezguine Y, Haurt J, et al. Conservative treatment of breast cancer: results and management of axillary lymph node area in 3353 patients. Lancet 1985;332;1387.
14. Falk SJ. Radiotherapy and the management of the axilla in early breast cancer. Br J Surg 1994;81:1277-81.
15. Fisher B, Redmond C, Poisson R. Eight year results of a randomised clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-8.
16. Haskel CM, Guiliano AE, Thompson RW, et al. Breast cancer. In: Dyson J, editor. Cancer treatment. Philadelphia, PA: Saunders, 1990:123-64.
17. Hancock BW, Bradshaw JD. Breast cancer. In: Hancock BW, editor. Lecture notes in clinical oncology. Oxford: Blackwell, 1986:81-8.
18. Norton L. Salvage therapy of breast cancer. Semin Oncol 1994;21:19-24.
19. Buick RN. 1994. Cellular basis of chemotherapy. In: Dorr RT, Hoff DD von, editors. Cancer chemotherapy handbook. Norwalk, CT: Appleton and Lange, 3-14.
20. Kiricuta CL, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:2496-501.
21. Coleman RE. 1996 Breast cancer. In: Hancock B, editor. Cancer care in the hospital. Oxford: Radcliffe Medical Press, 81-8.
22. Fisher B, Bauer M, Wickerham L, et al. Relation of number of positive axillary lymph nodes to the prognosis of patients with primary breast cancer. Cancer 1983;52:1551-7.
23. Pritchard KL. Current status of endocrine therapy for resectable breast cancer. Semin Oncol 1987;14:23-33.
24. Grahame-Smith DG, Aronson JK. Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 1992:692.
25. DeVita VT. Breast cancer therapy: exercising all our options. N Engl J Med 1989;320:527-9.
26. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490-5.
27. OShaughnessy JA, Cowan KH. Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 1995;33:27-37.
28. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer; a Phase II trial of the Clinical Screening Co-operative Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-22.
29. Sole LAJ, Bellmot J, Ribas A, et al. Phase II trial of an all-oral regime for tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer 1995;75:831-5.
30. Vandenberg TA. New developments in chemotherapy for metastatic breast cancer. Anticancer Drugs 1994;5:251-9.
31. Rakowski E, Sulkes A. Current developments in breast cancer. Curr Opin Obstet Gynecol 1993;5:490-6.
32. Harmenberg J, Hoglund M, Hellstrom-Lindberg E. G- and GM-CSF in oncology and oncological haematology. Eur J Haemotol 1994;52:1-28.
33. Moore MAS. The clinical use of colony stimulating factors. Annu Rev Immunol 1991;9:159-91.
34. Clavel M, Bonneterre J, Dallens H, et al. Oral ondansetron in the prevention of chemotherapy induced emesis in breast cancer patients. Eur J Cancer 1995;13:314-22.
35. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancencorrelation of relapse free survival with amplification of HER2/neu oncogene. Science 1987;235:177-82.
36. Peckham MJ. Clinical aspects of metastasis. In: Bock G, Whelan J, editors. Metastases. Ciba Foundation Symposium. Chichester: Wiley, 1988:223-43.
37. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-48.
38. Schuuring E, Verhoeven E, Van Tinteren H, et al. Amplification of genes within 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 1992;52:5229-34.
39. Watson JD, Hopkins NH, Roberts JW, et al. The genetic basis of cancer. In: Gillen JR, editor. Molecular biology of the gene. Menlo Park, CA: Benjamin/Cummings, 1989:1187-218.
40. Israel M. Molecular approaches to cancer therapy. Adv Cancer Res 1993;61:57-85.
41. Lindman H, Taube A, Bergh JCS. Suramin inhibits the growth of breast cancer cell lines studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein. Anticancer Res 1994;14:363-6.
42. Vignon F, Prebois C, Rochefort H. Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 1992;84:38-42.
43. Foekens JA, Sieuwerts AM, Dorssers LCJ, et al. Pleotropic effects of suramin on the proliferation of human breast cancer cells in vitro. Int J Cancer 1992;51:439-44.
44. Roitt IM, Brostoff J, Male DK. Immunity to tumours. In: Roitt IM, editor. Immunology. Edinburgh: Churchill Livingstone, 1985:18.118.17.
45. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85.
46. Sikora K, James N. Immune modulation and cancer. Br Med Bull 1991;47:209-26.
47. Culver KW, Blaese RM. Gene therapy for cancer. Trends Genet 1994;10:174-8.
48. Chouldhurg M, Efros M, Mittlelman A. IFN and ILNs in metastatic renal cell carcinoma. Urology 1993;141(Suppl):67-72.
49. Ferratini M, Giovarelli M, Modesti A, et al. IFN-alpha 1 gene expression in a metastatic murine adenocarcinoma (TS/A): results in CD8+ T cell-mediated tumour rejection and development of antitumour immunity: comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994; 153:4604-15.
50. Deng G, Chen LC, Schott DR, et al. Loss of heterozygosity and p53 gene-mutations in breast cancer. Cancer Res 1994;54:499-505.
51. Negrini M, Sabbioni S, Haldar S. Tumour and growth suppression of breast cancer cells by chromosome-17-associated functions Cancer Res 1994;54:1818-24.
52. Dear TN, Ramshaw IA, Kefford RF. Differential expression of a novel gene, WDNM1, in nonmetastatic rat mammary adenocarcinoma cells. Cancer Res 1989;48:5203-9.
53. Steeg PS, Bevilacqua G, Koppwe L. Evidence for a new novel gene associated with low tumour metastatic potential. J Natl Cancer Inst 1988;80: 200-4.